BioSpace News Archive

Aurinia Pharmaceuticals Inc. today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming investor healthcare conference.

PerkinElmer Launches EnVison Nexus Multimode Plate Reader to Drive Improved Research and Discovery Workflows.

Pharvaris today announced a poster detailing positive data from its Phase 2 RAPIDe-1 study of PHVS416 for the on-demand treatment of attacks will be presented at the American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, being held from February 24-27, 2023.

Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents.

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December 31, 2022.

Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas.

Bio-Techne Corporation announced that a newly finalized local coverage determination from National Government Services, Inc., a Medicare Administrative Contractor, includes coverage for the ExoDx™ Prostate Test from Exosome Diagnostics, a Bio-Techne brand.

Neogen Corporation has continued to report successes with the advancement of its Neogen® Analytics software program.

GT Biopharma, Inc. (NASDAQ: GTBP) today announced that Dr. Jeffrey Miller, MD, GT Bipharma’s Consulting Chief Medical Officer and Chief Scientific Officer, will present a corporate overview at H.C. Wainwright’s Cell Therapy Virtual Conference taking place on February 28, 2023.

Oscotec Inc. announced topline results for Phase 2 trial evaluating the efficacy, safety and tolerability of cevidoplenib (SYK inhibitor) in immune thrombocytopenia (ITP) patients who have failed to respond or relapsed after prior therapy.